Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (71-80 of 196) with videos related to

Pageof 20
Sort By:
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Functional determination of antithrombin III in clinical samples and therapeutic concentratesJ Fareed, J M Walenga, L G Svendsen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021O Iqbal, W Jeske, D Hoppensteadt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.
Mediators of Inflammation|January 1, 1993
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGFL E Silber, J M Walenga, J Fareed, et al.
Thrombosis and Haemostasis|August 26, 1998
Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cellsJ M Herbert, P Savi, W P Jeske, et al.
Pageof 20

Showing results (71-80 of 196) with videos related to

Sort By:
Pageof 20
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Functional determination of antithrombin III in clinical samples and therapeutic concentratesJ Fareed, J M Walenga, L G Svendsen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021O Iqbal, W Jeske, D Hoppensteadt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.
Mediators of Inflammation|January 1, 1993
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGFL E Silber, J M Walenga, J Fareed, et al.
Thrombosis and Haemostasis|August 26, 1998
Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cellsJ M Herbert, P Savi, W P Jeske, et al.
Pageof 20